
Guangzhou LBP Medicine Science & Technology Co., Ltd.
SSE:688393.SS
29.83 (CNY) • At close June 12, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 470.79 | 497.291 | 507.381 | 438.989 | 375.433 | 355.16 | 306.296 | 260.47 | 241.16 | 142.601 | 107.446 | 87.719 |
Cost of Revenue
| 154.255 | 161.872 | 146.75 | 96.947 | 75.964 | 57.943 | 52.174 | 43.207 | 42.746 | 46.271 | 37.429 | 30.766 |
Gross Profit
| 316.535 | 335.419 | 360.631 | 342.042 | 299.469 | 297.217 | 254.122 | 217.262 | 198.415 | 96.329 | 70.017 | 56.953 |
Gross Profit Ratio
| 0.672 | 0.674 | 0.711 | 0.779 | 0.798 | 0.837 | 0.83 | 0.834 | 0.823 | 0.676 | 0.652 | 0.649 |
Reseach & Development Expenses
| 40.9 | 62.687 | 67.394 | 45.902 | 27.732 | 21.859 | 15.586 | 15.305 | 13.251 | 10.617 | 15.98 | 0 |
General & Administrative Expenses
| 4.081 | 18.051 | 20.45 | 18.91 | 10.619 | 5.156 | 4.779 | 3.7 | 21.203 | 23.869 | 25.011 | 13.229 |
Selling & Marketing Expenses
| 105.716 | 181.663 | 185.975 | 179.594 | 153.556 | 161.883 | 141.808 | 122.84 | 112.572 | 31.626 | 14.327 | 14.677 |
SG&A
| 109.797 | 263.287 | 206.425 | 198.504 | 164.175 | 167.039 | 146.586 | 126.539 | 133.775 | 55.495 | 39.338 | 27.905 |
Other Expenses
| 154.836 | -12.068 | 55.206 | 30.591 | 11.821 | 20.047 | 0.11 | -0.571 | 8.287 | 3.977 | 2.385 | 4.447 |
Operating Expenses
| 305.533 | 319.104 | 329.025 | 274.997 | 203.729 | 208.944 | 179.434 | 157.3 | 150.026 | 57.217 | 40.399 | 29.246 |
Operating Income
| 11.002 | 21.513 | 38.853 | 88.94 | 100.196 | 88.796 | 74.363 | 60.646 | 46.983 | 40.262 | 29.906 | 27.342 |
Operating Income Ratio
| 0.023 | 0.043 | 0.077 | 0.203 | 0.267 | 0.25 | 0.243 | 0.233 | 0.195 | 0.282 | 0.278 | 0.312 |
Total Other Income Expenses Net
| -1.567 | -4.663 | -10.062 | -0.216 | -0.343 | -1.548 | 0.11 | -0.571 | 8.287 | 3.977 | 2.385 | 4.447 |
Income Before Tax
| 9.434 | 16.849 | 28.791 | 88.724 | 99.853 | 87.248 | 74.473 | 60.075 | 55.269 | 44.24 | 32.291 | 31.788 |
Income Before Tax Ratio
| 0.02 | 0.034 | 0.057 | 0.202 | 0.266 | 0.246 | 0.243 | 0.231 | 0.229 | 0.31 | 0.301 | 0.362 |
Income Tax Expense
| -5.466 | -4.17 | -0.539 | 13.441 | 16.231 | 14.444 | 12.053 | 10.333 | 8.41 | 5.836 | 4.557 | 4.638 |
Net Income
| 21.291 | 40.057 | 29.33 | 79.776 | 84.746 | 73.989 | 61.472 | 48.339 | 46.029 | 38.431 | 27.734 | 27.15 |
Net Income Ratio
| 0.045 | 0.081 | 0.058 | 0.182 | 0.226 | 0.208 | 0.201 | 0.186 | 0.191 | 0.27 | 0.258 | 0.31 |
EPS
| 0.23 | 0.43 | 0.31 | 0.85 | 0.91 | 0.79 | 0.88 | 0.69 | 0.66 | 0.55 | 0.4 | 2.71 |
EPS Diluted
| 0.22 | 0.42 | 0.31 | 0.85 | 0.91 | 0.79 | 0.88 | 0.69 | 0.66 | 0.55 | 0.4 | 2.71 |
EBITDA
| 50.836 | 66.481 | 71.389 | 111.256 | 111.569 | 99.603 | 87.746 | 73.794 | 67.353 | 42.878 | 32.577 | 30.987 |
EBITDA Ratio
| 0.108 | 0.134 | 0.141 | 0.253 | 0.297 | 0.28 | 0.286 | 0.283 | 0.279 | 0.301 | 0.303 | 0.353 |